Nara
← Intervention Library

Experimental and investigational

LOY-002

An investigational senior-dog longevity candidate.

Nara’s current positionClinical-trial only
Evidence briefing

Strongest directness: Canine safety / pharmacokinetics. Last reviewed 2026-08-12.

Nara’s evidence view

Clinical-trial context only

Hypothesis-generatingCanine safety or pharmacokineticsVery low confidence

The claim we’re evaluating

LOY-002 has substantial ongoing canine clinical-development and target-animal safety evidence, but no publicly reported pivotal result currently demonstrates that LOY-002 extends canine healthspan or lifespan.

Nara’s interpretation

LOY-002 is one of the most advanced canine longevity drug programs, but advanced development is not the same thing as demonstrated efficacy. FDA has accepted both its Reasonable Expectation of Effectiveness and Target Animal Safety sections, while the large randomized STAY study remains the study intended to establish whether treatment actually affects survival and health. Nara should therefore describe LOY-002 as a serious clinical experiment rather than a proven longevity intervention.

Personalized

What this means for your dog.

Loading your dog’s context…

Evidence briefing

What Nara knows now.

A bounded position while the full claim-level dossier is still being completed.

What is known

Loyal reports that FDA accepted LOY-002's Reasonable Expectation of Effectiveness section in 2025 and its Target Animal Safety section in late 2025, announced January 2026. The disclosed safety package included a standard target-animal safety study at multiples of intended exposure and field-safety experience in more than 400 dogs, including dogs followed for up to one year, with no clinically significant adverse events reported at the tested multiples. Detailed underlying safety data remain incompletely public. STAY is a fully enrolled double-blinded placebo-controlled study involving roughly 1,300 dogs and is the pivotal effectiveness study for LOY-002. Enrollment and regulatory progress are not efficacy outcomes.

What is not known

The active pharmaceutical ingredient and exact mechanism remain undisclosed publicly, limiting independent pharmacologic evaluation. The RXE standard is not the substantial-evidence standard for full approval. The accepted Target Animal Safety section provides meaningful safety evidence but does not establish efficacy. STAY remains blinded/in development; enrollment provides no information about whether efficacy will be positive, null, or harmful.

Current position

LOY-002 is one of the most advanced canine longevity drug programs, but advanced development is not the same thing as demonstrated efficacy. FDA has accepted both its Reasonable Expectation of Effectiveness and Target Animal Safety sections, while the large randomized STAY study remains the study intended to establish whether treatment actually affects survival and health. Nara should therefore describe LOY-002 as a serious clinical experiment rather than a proven longevity intervention.

Loyal reports that FDA accepted LOY-002's Reasonable Expectation of Effectiveness section in 2025 and its Target Animal Safety section in late 2025, announced January 2026. The disclosed safety package included a standard target-animal safety study at multiples of intended exposure and field-safety experience in more than 400 dogs, including dogs followed for up to one year, with no clinically significant adverse events reported at the tested multiples. Detailed underlying safety data remain incompletely public. STAY is a fully enrolled double-blinded placebo-controlled study involving roughly 1,300 dogs and is the pivotal effectiveness study for LOY-002. Enrollment and regulatory progress are not efficacy outcomes.